35496319|t|Major Bleeding Risk in Atrial Fibrillation Patients Co-Medicated With Non-Vitamin K Oral Anticoagulants and Antipsychotics.
35496319|a|Major bleeding risks associated with non-vitamin K oral anticoagulants (NOACs) used with and without concurrent antipsychotics in patients with non-valvular atrial fibrillation (AF) were assessed. A total of 98,863 patients with non-valvular AF receiving at least one NOAC prescription from Taiwan's National Health Insurance database were enrolled. Major bleeding was defined as a primary diagnosis of intracranial or gastrointestinal hemorrhage or bleeding at other sites. The adjusted incidence rate difference (AIRD) per 1,000 person-years and adjusted rate ratio of major bleeding were estimated using Poisson regression and inverse probability of treatment weighting using the propensity score. A total of 8,037 major bleeding events occurred during 705,521 person-quarters with NOAC prescriptions. Antipsychotics were used in 26.35% of NOAC-exposed patients. Compared to using NOAC alone, co-medication of either typical (AIRD: 79.18, 95% confidence interval [CI]: 70.63-87.72) or atypical (AIRD: 40.5, 95% CI: 33.64-47.35) antipsychotic with NOAC had a significant increase in the adjusted incidence rate per 1,000 person-years of major bleeding. The concomitant use of a NOAC with chlorpromazine (AIRD: 103.87, 95% CI: 51.22-156.52), haloperidol (AIRD: 149.52, 95% CI: 125.03-174.00), prochlorperazine (AIRD: 90.43, 95% CI: 78.55-102.32), quetiapine (AIRD: 44.6, 95% CI: 37.11-52.09), or risperidone (AIRD: 41.55, 95% CI: 22.86-60.24) (All p < 0.01) showed a higher adjusted incidence rate of major bleeding than using NOACs alone. The concomitant use of typical (chlorpromazine, haloperidol, or prochlorperazine) or atypical (quetiapine or risperidone) antipsychotic with NOACs was associated with a significantly increased risk of major bleeding.
35496319	6	14	Bleeding	Disease	MESH:D006470
35496319	23	42	Atrial Fibrillation	Disease	MESH:D001281
35496319	43	51	Patients	Species	9606
35496319	74	103	Vitamin K Oral Anticoagulants	Chemical	-
35496319	130	138	bleeding	Disease	MESH:D006470
35496319	165	194	vitamin K oral anticoagulants	Chemical	-
35496319	196	201	NOACs	Chemical	-
35496319	254	262	patients	Species	9606
35496319	281	300	atrial fibrillation	Disease	MESH:D001281
35496319	302	304	AF	Disease	MESH:D001281
35496319	339	347	patients	Species	9606
35496319	366	368	AF	Disease	MESH:D001281
35496319	392	396	NOAC	Chemical	-
35496319	480	488	bleeding	Disease	MESH:D006470
35496319	527	570	intracranial or gastrointestinal hemorrhage	Disease	MESH:D006471
35496319	574	582	bleeding	Disease	MESH:D006470
35496319	701	709	bleeding	Disease	MESH:D006470
35496319	848	856	bleeding	Disease	MESH:D006470
35496319	909	913	NOAC	Chemical	-
35496319	967	971	NOAC	Chemical	-
35496319	980	988	patients	Species	9606
35496319	1008	1012	NOAC	Chemical	-
35496319	1174	1178	NOAC	Chemical	-
35496319	1269	1277	bleeding	Disease	MESH:D006470
35496319	1304	1308	NOAC	Chemical	-
35496319	1314	1328	chlorpromazine	Chemical	MESH:D002746
35496319	1367	1378	haloperidol	Chemical	MESH:D006220
35496319	1418	1434	prochlorperazine	Chemical	MESH:D011346
35496319	1472	1482	quetiapine	Chemical	MESH:D000069348
35496319	1521	1532	risperidone	Chemical	MESH:D018967
35496319	1632	1640	bleeding	Disease	MESH:D006470
35496319	1652	1657	NOACs	Chemical	-
35496319	1697	1711	chlorpromazine	Chemical	MESH:D002746
35496319	1713	1724	haloperidol	Chemical	MESH:D006220
35496319	1729	1745	prochlorperazine	Chemical	MESH:D011346
35496319	1760	1770	quetiapine	Chemical	MESH:D000069348
35496319	1774	1785	risperidone	Chemical	MESH:D018967
35496319	1806	1811	NOACs	Chemical	-
35496319	1872	1880	bleeding	Disease	MESH:D006470
35496319	Positive_Correlation	MESH:D011346	MESH:D006470
35496319	Positive_Correlation	MESH:D000069348	MESH:D006470
35496319	Positive_Correlation	MESH:D006220	MESH:D006470
35496319	Negative_Correlation	MESH:D000069348	MESH:D001281
35496319	Positive_Correlation	MESH:D018967	MESH:D006470
35496319	Positive_Correlation	MESH:D002746	MESH:D006470

